Thursday 28 September, Sydney, Australia

Sydney-based biotech Minomic International Ltd is delighted to announce that the company’s ground-breaking test for prostate cancer, MiCheck® Prostate, has received its first reimbursement in the United States from the Centres for Medicare and Medicaid Services (CMS).

MiCheck® Prostate is commercially available through Minomic’s CLIA Certified “High Complexity” Laboratory located in Gaithersburg, Maryland.

Receiving reimbursement for MiCheck® Prostate is a significant step in the company’s commercialisation rollout in the world’s largest healthcare market and will significantly accelerate adoption of the test by American healthcare providers. The reimbursement amount was consistent with the company’s forecast selling price.

Minomic CEO, Dr Brad Walsh said:

“Gaining reimbursement for MiCheck® Prostate in the United States is a wonderful boost. Not just for Minomic, but for American patients. Reimbursement through CMS will greatly broaden MiCheck® Prostate’s availability to American men.


We currently have 15 urology practices referring patients for MiCheck® Prostate with new practices being regularly being added. We look forward to continuing productive discussions with members of the healthcare community about MiCheck® Prostate and Minomic.”